What is the role of neoadjuvant chemotherapy in the treatment of locoregional breast cancer?

Updated: May 21, 2019
  • Author: Erin V Newton, MD; Chief Editor: Neetu Radhakrishnan, MD  more...
  • Print


The NSABP B-18 trial found no significant difference in overall survival or disease-free survival between patients with operable breast cancer randomized to neoadjuvant chemotherapy and patients treated with surgery first and then followed by chemotherapy. However, survival advantage was significant for the 36% of patients who experienced a pCR.

Given the notorious propensity of IBC for locoregional as well as systemic recurrence, patients with this disease are nearly always best served by having mastectomy as their definitive surgery.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!